(Q35172774)

6 August 2017

1 reference

title

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer (English)

1 reference

6 August 2017

1 reference

Srikala S Sridhar

1

1 reference

6 August 2017

Lesley Seymour

series ordinal

2

1 reference

6 August 2017

Frances A Shepherd

series ordinal

3

1 reference

6 August 2017

publication date

1 July 2003

1 reference

Lancet Oncology Commission

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

397-406

1 reference

6 August 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Trastuzumab in the treatment of non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

A new antibody recognizing the vIII mutation of human epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

CI-1033, a pan-erbB tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901137-9

7 January 2021

10.1016/S1470-2045(03)01137-9

Identifiers

DOI

1 reference

6 August 2017

1 reference